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Introduction   
In the early evolution of Western medicine, the diagnosis 
of diseases was mainly based on pattern recognition 
of clinical manifestations. Capturing accurate medical 
history and performing precise physical examination are 
indispensable skill that all clinicians have to acquire. 
Such traditional diagnostic maneuver remains a gold 
standard for a long while and is still very important 
for timely clinical management. Subsequently, the 
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AbSTRACT 
The gold standard of cancer diagnosis has long been based on histological 
characteristics. With the rapid advancement of genetic medicine, such 
standard algorithm of diagnostic approach is facing a challenge. The genetic 
findings have been changed from being a “supporting character” into the role 
of a “main character”. More and more disease diagnosis and classification 
has to be defined by genetic basis. In this article, we focus on the challenges 
in the field of pediatric oncology. We cited 2 scenarios where genetic 
information plays a pivotal role in identifying the underlying pathology. 
The first scenario is that same genetic mutation can lead to variable 
clinical phenotypes, this includes EWSR1-PATZ1 fusion related neoplasms; 
BCOR neoplasms; and GATA-2 deficiency related immunodeficiency and 
myelodysplastic syndrome. Another scenario is relatively more common 
that is the same clinical and histopathological phenotype with different 
underlying genotypes. The genotypes actually impact on the treatment 
response and outcome. We used medulloblastoma as an example. In fact, 
we can also find similar scenario in many pediatric cancers such as Ewing 
sarcoma, ependymoma, etc. The essence of this article is to remind clinicians 
of the rapid development in genetic medicine and it has been reshaping the 
landscape of the modern disease classification and therapeutic approach. In 
the near future, it may even lead to a paradigm shift in our disease diagnostic 
algorithm.  
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industrial revolution led to rapid advances in technology. 
The gold standard in diagnosis gradually shifted to 
pathological methods. For cancers diagnosis, microscopic 
examination of the affected tissues obtained by biopsy 
is what we have been relying on since then. The use of 
immuno-histochemical staining further strengthened 
the reliability of such approach. Up to the current era, 
majority of pediatric cancers are classified based on 
specific histopathological findings. But in a significant 
number of cases, we may not be able to draw a definite 
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conclusion by this approach. Under this circumstance, 
conflicting results may be given by different pathologists 
and the interpretation can be subjective. Another more 
common situation is that even with the same clinical and 
pathological classification of a specific cancer phenotype, 
we notice heterogeneity in the treatment outcome. What 
may contribute to this variation has been puzzling many 
oncologists for a long time. Effort in looking for risk 
factors based on either clinical features or biological 
markers has been applied over the past decades. Recently, 
with the rapid development in molecular genetics, we 
noticed that the heterogeneity of the same disease may be 
contributed by underlying genetic variances. Such genetic 
variations may affect the disease manifestations directly 
or indirectly, or it may affect the treatment response. 
We would like to highlight some of such situations and 
presented several cases as examples. We are foreseeing 
genetic and genomic information will inevitably impact on 
our future practice in pediatric oncology. 
Same genetic mutation with variable clinical 
phenotypes
The conventional wisdom is that if we identify a specific 
genetic mutation, we expect the clinical phenotype 
will be similar across the board. In fact, the existing 
algorithm of pathological diagnosis is defined by the 
immunohistochemistry first and then verified by genetic 
information. In many occasions, the genetic information 
is considered as either academic interest or additional 
prognostic markers. But with molecular genetic testing 
getting more readily available and its usage becoming 
more widespread, we started to notice such algorithm may 
be misleading. In fact, clinicians notice under the same 
genetic aberration, very diverse clinical phenotypes and 
histological features can be derived. Several examples are 
cited here to illustrate such situation.
 EWSR1-PATZ1 fusion related neoplasms
A 5-year-old boy was noted to have a swelling over his 
right angle of the mandible since he was 1.5-year-old. The 
swelling gradually increased in size and initial investigation 
by ultrasonography and CT scan showed a cystic mass with 
high vascular signal. He was treated empirically as vascular 
malformation with local sclerosing agent at a regional hospital. 
There was no response and the mass further progressed 
and some solid components started to emerge in repeated 
ultrasonography. The solid mass subsequently became the 
dominant part of the lesion. Biopsy was performed and it 
showed small blue round cell tumor and it was diagnosed 
as peripheral primitive neuroectodermal tumor (pPNET) 
with CD99 positivity. pPNET has a very diverse clinical 
pattern and is relatively more common in Chinese 
children.1 He was eventually referred to us and the lesion 
already progressed into a large mandibular swelling with 
multiple lung metastases. Pathologists around the world 
were consulted with different opinions given. The final 
consensus was “high grade undifferentiated tumor”. 
Specimens were sent for genetic testing using RNAseq 
panel including a variety of fusion genes and it turned out 
to be positive for EWSR1-PATZ1.2 Then it was diagnosed 
as “EWSR1-PATZ1 sarcoma”. He was treated according to 
the Ewing sarcoma regimen3 and he achieved good partial 
response with the treatment.
EWSR1-PATZ1 (Ewing Sarcoma Breakpoint Region 1 - 
POZ/BTB and AT Hook Containing Zinc Finger 1) gene 
fusion was first discovered in small round cell sarcoma.4 
Later on, tumors with EWSR1-PATZ1 fusion were found to 
exhibit highly variable clinical behavior which is distinct 
from Ewing sarcoma (Table 1). Their immunophenotype 
and pathological morphology also varies.5 Secondary 
genetic changes such as CDKN2A/CDKN2B loss are 
common and they contribute to oncogenesis. EWSR1-
PATZ1 neoplasm can present as a mass over the head and 
neck, chest wall, extremities or even lung. Interestingly, 
it can also present as brain tumors.6 There is no age and 
sex predilection and morphologically, it can be classified 
as undifferentiated sarcoma, alveolar rhabdomyosarcoma 
and primitive neuroectodermal tumor. In the brain, it 
can be diagnosed as glioma, primitive neuroectodermal 
tumor, and even pleomorphic xanthroastrocytoma.6 The 
immunophenotype does not show a consistent pattern.  
TAble 1 The EWSR1-PATZ1 malignancies can be summarized as 
different categories 
Type of tumor Subtype
Sarcoma Undifferentiated round cell sarcoma, alveolar 
rhabdomyosarcoma
Brain tumor Primitive neuroectodermal tumor, pleomorphic 
xanthoastrocytoma, glioma, ganglioglioma, 
ventricular cystic glioneuronal tumor, undifferentiated 
sarcoma
Carcinoma Soft tissue myoepithelial neoplasm
Then the problem arises, should we treat these tumors 
according to their histological classification or should we 
treat them based on the underlying genetic aberration? 
Due to the rarity of cases reported so far and they were 
mostly treated according to their respective histological 
classification, we do not have a clear answer to this 
question based on the current published data. 
BCOR neoplasms
A 5-month-old girl was noted to have a cystic swelling 
over the dorsum of her left foot. Ultrasonography 
suggested lymphatic malformation. However, aspiration 
biopsy showed atypical spindle cells which were stained 
positive for CD99. It was diagnosed as pPNET by a 
renowned centre in China. It is known that pPNET can 
be found in infancy.7 But the family decided to seek 
2nd opinion in another hospital, where incision biopsy 
was performed and the pathology suggested infantile 
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fibrosarcoma. However, genomic study failed to show any 
NTRK fusions. No treatment was offered while waiting 
for further study, the tumor progressed rapidly and she 
developed extensive lung, bone and lymph node metastasis 
within the next 4 months. She was brought to our hospital 
and after careful evaluation the diagnosis of primitive 
myxoid mesenchymal tumor of infancy was made.8 
Immuno-histochemical stains showed that it was positive 
for both BCOR and BCl6. Subsequent PCR confirmed 
BCOR internal tandem duplication (ITD) abnormality 
which is typical for BCOR sarcoma in infancy. She was 
treated with irinotecan and temozomide9 with the addition 
of apatinib10 and she achieved good partial response after 
3 courses of treatment. 
BCOR (BCL-6 corepressor) is part of the noncanonical 
polycomb repressive complex 1 and its main function 
is to serve as an epigenetic control to regulate cellular 
differentiation in body structure development.11 Germline 
BCOR loss-of-function mutations will lead to oculo-
facio-cardio-dental syndrome, with an X-linked dominant 
inheritance. Somatic BCOR aberrations (mainly BCOR-
CCNB3, BCOR-MAML3 and ZC3H7B-BCOR), can 
drive the development of various sarcomas and CNS 
neoplasms (i.e. CNS HGNET-BCOR). Other loss of 
function mutations in BCOR recur in a large variety of 
mesenchymal, epithelial, neural and even hematological 
malignancies (Table 2).12
TAble 2 The BCOR neoplasms can be summarized as different 
categories 
Type of tumor Subtype
Sarcoma
Clear cell sarcoma of kidneys, primitive myxoid 
mesenchymal tumor of infancy, undifferentiated 
sarcoma, EWS-like sarcoma (mostly with 
CCNB3 fusion), round cell sarcoma of bone, 
rhabdomyosarcoma
Brain tumor Medulloblastoma (esp. SHH subtype), high grade glioma, high grade embryonal tumor
Hemic malignancies MDS, AML, CMML, NHL (rare forms such as EN-NK, T-NHL)
Carcinoma Salivary glands CA, endometrial CA, thymic CA, etc
EWS, Ewing sarcoma; CCNB3, Cyclin B3; SHH, sonic hedgehog; MDS, 
myelodysplastic syndrome; AML, acute myeloid leukemia; CMML, chronic 
myelomonocytic leukemia; NHL, non-Hodgkin lymphoma; EN-NK, extra nodal 
natural killer cells lymphoma; T-NHL, T non-Hodgkin lymphoma; CA, carcinoma. 
GATA-2 deficiency associated hematological malignancies 
& immunological disorders
A 3-month-old girl presented with pallor and her complete 
blood picture showed pancytopenia. Bone marrow aspiration 
and trephine biopsy showed hypoplastic marrow and 
cytogenetic revealed monosomy 7. Deoxybutane (DEB) test 
did not demonstrate any increase in chromosomal breakage. 
Then repeated bone marrow examination 6 months later 
revealed hypoplasia with dysmegakaryopoiesis, compatible 
with myelodysplastic syndrome and karyotyping still showed 
monosomy 7 abnormality. She was put on supportive care 
including occasional packed red blood cell transfusion 
while waiting for hematopoietic stem cell transplantation. 
Subsequently, molecular genetic test revealed that the patient 
has germline de novo heterozygous GATA-2 mutation leading 
to haplo-insufficiency. 
“GATA” is a family of transcription factors characterized 
by their ability to bind to the DNA sequence “-GATA-
” and it consists of six proteins (GATA-1 to 6). GATA-
1/2/3 are required for differentiation of mesoderm and 
ectoderm-derived tissues, including the hematopoietic 
and central nervous system,13,14 whereas GATA-4/5/6 
are implicated in the development and differentiation 
of endoderm- and mesoderm-derived tissues such as 
induction of differentiation of embryonic stem cells, 
cardiovascular embryogenesis and guidance of epithelial 
cell differentiation in the adult. 
Three mutations are found in GATA-2 deficient patients 
and they are truncating mutations prior to zinc finger 2 
(ZF2); missense mutations within ZF2; and non-coding 
variants in the regulatory region of GATA-2.15 Germline 
GATA-2 deficiency is associated with highly variable 
clinical phenotypes. It can be very mild such as in the 
case of sporadic neutropenia. However, some children 
present with a much more severe immunodeficiency due 
to the involvement of monocytic and lymphoid lineages 
(MonoMAC syndrome and DCML deficiency).16,17 Due to the 
underlying immunodeficiency, they may develop cutaneous 
atypical Mycobacterium infection18; recalcitrant periungual 
warts and perineal condyloma. In some patients, they may 
even have viral associated neoplasm such as Epstein-Barr 
Virus-related spindle cell tumor.19 Other from deficiency 
or dysfunction of the immune cells, they can develop 
myelodysplastic syndrome with monosomy 7 anomaly 
and some evolves into acute myeloid leukaemia.20 In 
addition to the hematological anomalies, structural defect 
in terms of lymphatic malformation, congenital deafness, 
and pulmonary alveolar proteinosis can be found in some 
patients.21 The clinical spectrum of germline GATA-2 
deficiency is summarized in Table 3. 
TAble 3 The GATA-2 deficiency clinical spectrum can be summarized 
into different categories 
Syndromes Features
Neutropenia Unexplained  neutropenia
MonoMAC syndrome Monocytopenia with predisposition to non- tuberculous mycobacterial infection
DCML deficiency Syndrome  o f  l ow  dendr i t i c  ce l l s , monocytes, B  and natural killer cells 
Emberger syndrome Primary lymphedema, congenital deafness, warts, low CD4
Familial MDS/AML Early onset MDS/AML
Primary Childhood MDS Childhood MDS
MonoMAC, monocytopenia and mycobacterial infection; DCML, dendritic cells, 
monocytes, B and natural killer lymphoid; MDS, myelodysplastic syndrome; AML, 
acute myeloid leukemia.
207Pediatr Investig 2020 Sep; 4(3): 204-210
The clinical hints to suspect GATA-2 deficiency including 
positive familial history and patients with myelodysplastic 
syndrome (MDS) associated with either monosomy 7 or 
trisomy 8.22 For adolescent with MDS associated with 
monosomy 7, up to 72% may have GATA-2 deficiency. 
And around 1/3 of childhood monosomy 7 syndrome are 
due to GATA-2 deficiency. Other manifestations of GATA-
2 deficiency includes immunodeficiency (39%); B cells 
lymphopenia; lymphedema with or without hydrocele 
(23%); congenital deafness (9%); urinary tract anomalies 
including vesicoureteric reflux and kidney asymmetry 
(12%); and behavioral problems such as attention deficit 
and hyperactive disorders or autism (12%). 
Same clinical and pathological phenotypes 
with different genotypes
Since the same genetic aberration may lead to highly 
variable disease phenotypes, we should naturally expect 
under the same histologically defined disease, there may 
be different genetic mutations. We noticed these genetic 
mutations also implicate on the clinical outcome. This 
makes molecular genetic testing an essential component 
of modern diagnostic armamentarium. There are several 
examples to support this observation.  
Medulloblastoma with variable genetic mutations 
A 14-month-old infant presented with history of on 
and off vomiting and irritability for the past 4 weeks. 
The vomiting was just once in a few days initially but 
lately, the frequency increased to almost daily and 
his parents noted that he developed convergent squint 
and refused walking. MRI showed a huge cerebellar 
tumor arising from the vermis and obliterating the 4th 
ventricle with obstructive hydrocephalus. Emergent 
external shunt was performed and then the tumor was 
gross totally removed. Histology was compatible with 
medulloblastoma of classical morphology and molecular 
genetic profile matched that of Group 3 subgroup with 
C-MYC amplification. Subsequent spine MRI showed 
multiple small nodular metastases over the leptomeningeal 
canal. He was given chemotherapy based on the HeadStart 
regimen23 with the intention to avoid irradiation. After 5 
courses of chemotherapy, he achieved stable disease status 
but the spinal lesions persisted. 
For medulloblastoma, it was traditionally classified into 
classical, desmoplastic [nodular & extensive nodular, 
(DN & EN)] and large cell anaplastic (LCA) types based 
on morphological characteristics.24 The prognosis differs 
among these morphological types but some heterogeneity 
was noted. We can now reclassify them more precisely 
into 4 major subgroups based on underlying somatic 
molecular genetic aberrations.25,26 The current data 
shows that the same morphological classification may 
have different genetic aberrations which impact on the 
prognosis. The clinical phenotype and prognosis correlate 
better with the molecular genetic subtype rather than 
the histological phenotype (Table 4).27 Lately, further 
molecular subgrouping can define the prognosis even 
better.28 
In the past, infant with medulloblastoma is considered as 
having poor prognosis with the exception of those with 
desmoplastic histology. It was speculated that it is due to 
the avoidance or delay of irradiation accounting for such 
adverse outcome. With the genetic grouping available, we 
can have a clearer insight of the underlying reason and this 
also helps us to design appropriate treatment strategy in 
the future. 
Discussion
With the advancement of molecular genetic technology, 
genetic information is becoming more readily available 
and affordable. More and more new data can now be 
gathered to re-classify pediatric neoplastic disorders. It 
gives us insight as of how the genetic mutation may impact 
on the disease development, biological characteristics, 
disease phenotype, treatment response and prognosis. In 
this article, we cited several examples to illustrate the fact 
that: 1) same genetic mutation can lead to variable clinical 
phenotypes; 2) same clinical and pathological phenotype 
can have different underlying genetic aberrations. Actually, 
these 2 observations are like mirror images verifying the 
TAble 4 Medulloblastoma can be summarized as 4 molecular genetic subgroups and they have overlapping morphological diagnosis 
Group Clinical phenotype Morphology & prognosis




WNT More in adolescent,




(C-MYC amplification +) 6−
Sonic Hedgehog 
(SHH) 
M o r e  i n  e i t h e r  i n f a n t 
or  older  chi ldren,M=F, 
uncommonly metastasis
Desmoplastic, classic and 






Group 3 More in infant & young 





(C-MYC amplification +++) 1q+, 7+, 17q+, i17q, 18q+,  5q−, 8−, 10q−, 11p−, 16q−






(CDK6 amplification, Seldom 
with either MYC amplification)
7+, 17q+, 18q+,
x−, 8−, 11p−
M, male; F, female; LCA, large cell anaplastic. 
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same philosophy that the genetic diagnosis is important in 
disease classification. We need to rely on such information 
to stratify our patients more precisely and accurately for 
designated treatment. 
The classical approach of pathological diagnosis for 
childhood cancers is to get the tissue and performed 
immuno-histochemical stains, the diagnosis is based on 
both morphology under the microscope and the expression 
of specific disease related proteins. But in recent years, 
we noticed that we have to rely more and more on the 
genetic information in order to stratify the patients 
into different risk groups. This risk stratified treatment 
approach is the standard for childhood acute lymphoblastic 
leukemia nowadays. In addition, the genetic mutation 
information can help us to perform minimal residual 
disease monitoring so timely treatment modification can 
be instituted. Furthermore, some genetic mutations can 
identify actionable targets so specific targeted therapy can 
be applied.29,30
Pediatric sarcomas and brain tumors are known to 
have highly variable histological classification based 
on traditional immunohistochemical approach. Their 
development in management has been lagging behind 
that of pediatric leukemia, partly it is due to the relative 
difficulty in getting tissue for diagnosis when compares 
to leukemia, and also the rarity of each specific type of 
tumors. With the help of molecular diagnostic technology, 
many hindrances in the past have been overcome. The 
molecular diagnosis usually needs a relatively small 
amount of tissue. With the success of liquid phase biopsy, 
the progress of certain solid tumors such as metastatic 
neuroblastoma and rhabdomyosarcoma can now be 
monitored by either bone marrow or even peripheral blood 
samples.31,32 
But when we propose to apply genetic diagnosis, it is not 
just confining to a few commonly used techniques such 
as RT-PCR, FISH, panel NGS33 or sequencing (WES or 
WGS).34 In recent years, the molecular genetic diagnostic 
approach also extends to looking at the transcriptome 
(i.e. RNAseq)35 and epigenetic profiles including the 
methylation profile; histone acetylation profile; expression 
of miRNA; and other non-coding RNAs. For example, 
undifferentiated sarcoma36 and pediatric central nervous 
system primitive neuroectodermal tumor37 have been 
reclassified by the methylation profile and it reveals 
interesting yet complex pattern of different diseases being 
classified into a single category previously. 
Even for the molecular diagnosis approach, there are 
disagreements on the approach. In adult solid tumors, 
most laboratories tend to perform panel NGS as the initial 
screening. If it fails, then most pathologists will proceed to 
either WES or WGS. Such algorithm may not be suitable 
for pediatric solid tumors due to the rarity and highly 
complex categories involved. Therefore, some pathologists 
prefer to go for WES or even WGS right away when they 
encounter difficult cases. It will depend on the strength of 
bioinformatics support if such approach is adopted for vast 
amount of data can be generated and it may be confusing 
to interpret. 
Another argument is whether we should adopt a 
histological approach first follows by genetic confirmation 
or genetic approach first followed by histological 
confirmation? It is a difficult and complex question to 
answer. Most pathologists will prefer the histological 
approach and supplement with genetic testing. However, 
we start to notice an emerging reversed, that means some 
pathology laboratory just performed minimal histological 
tests for screening and then jumped to the genetic testing 
right away. Despite criticism, whether this approach will 
become the main approach remains to be observed. Some 
even foresees that such scenario is comparable to the 
story of digital camera versus filmed camera, the outcome 
eventually will be decided by the consumers. In this 
regards, the patients and the clinicians are the consumers 
and their preference may influence the outcome of such 
development. 
No matter which algorithm that we follow, the best 
approach nowadays is to have a multi-disciplinary tumor 
board so the clinical information, imaging characteristics, 
pathological findings and genetic data can all be integrated 
before logical therapeutic approach can be formulated. For 
pediatric tumors, due to the rarity of specific tumor types, 
international collaboration is highly recommended so the 
genomic and epigenomic data can be shared and properly 
analyzed.
To summarize, pediatric cancers are rare and yet with 
many varieties based on histological classifications. 
The rarity and heterogeneity issues among different 
tumor types often create difficulties for the clinicians in 
conducting clinical studies. It is because it often takes 
years to recruit adequate subjects to answer the questions. 
With the rapid development of genetic and genomic 
medicine, more precise grouping and classification can 
now be achieved and this also means the required study 
sample size will be even more difficult to fulfill. There 
should be an international effort to coordinate clinical 
study based on the new diagnostic information. In the past, 
most clinical trials for pediatric cancers were conducted 
in America and Europe. With 70% of world population 
residing in Asia and the basic health care condition 
improving, new paradigm has to be established. The 
Asian pediatric pathologists and oncologists should work 
together to set up a common platform for clinical trial. 
Then we can work with our colleagues around the world 
to advance our knowledge in managing childhood cancers. 
ACKNOWleDGeMeNTS 
We would like to thank the Children’s Cancer Foundation 
209Pediatr Investig 2020 Sep; 4(3): 204-210





 1. Khong PL, Chan GC, Shek TW, Tam PK, Chan FL. Imaging 
of peripheral PNET: Common and uncommon locations. 
Clin Radiol. 2002;57:272-277.
 2. Watson S, Perrin V, Guillemot D, Reynaud S, Coindre 
JM, Karanian M, et al. Transcriptomic definition of 
molecular subgroups of small round cell sarcomas. J Pathol. 
2018;245:29-40.
 3. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, 
Le Deley MC, et al. Ewing sarcoma: Current management 
and future approaches through collaboration. J Clin Oncol. 
2015;33:3036-3046.
 4. Mastrangelo T, Modena P, Tornielli S, Bullrich F, Testi MA, 
Mezzelani A, et al. A novel zinc finger gene is fused to EWS 
in small round cell tumor. Oncogene. 2000;19:3799-3804.
 5. Bridge JA, Sumegi J, Druta M, Bui MM, Henderson-
Jackson E, Linos K, et al. Clinical, pathological, and 
genomic features of EWSR1-PATZ1 fusion sarcoma. Mod 
Pathol. 2019;32:1593-1604.
 6. Siegfried A, Rousseau A, Maurage CA, Pericart S, Nicaise 
Y, Escudie F, et al. EWSR1-PATZ1 gene fusion may define a 
new glioneuronal tumor entity. Brain Pathol. 2019;29:53-62.
 7. Chan GC, Nicholls JM, Lee AC, Chan LC, Lau YL. 
Malignant peripheral neuroectodermal tumor in an infant 
with neurofibromatosis type 1. Med Pediatr Oncol. 
1996;26:215-219.
 8. Cramer SL, Li R, Ali S, Bradley JA, Kim HK, Pressey 
JG. Successful treatment of recurrent primitive myxoid 
mesenchymal tumor of infancy with BCOR internal tandem 
duplication. J Natl Compr Canc Netw. 2017;15:868-871.
 9. Kurucu N, Sari N, Ilhan IE. Irinotecan and temozolamide 
treatment for relapsed Ewing sarcoma: A single-center 
experience and review of the literature. Pediatr Hematol 
Oncol. 2015;32:50-59.
10. Wang Y, Min L, Zhou Y, Luo Y, Duan H, Tu C. The 
efficacy and safety of apatinib in Ewing’s sarcoma: A 
retrospective analysis in one institution. Cancer Manag Res. 
2018;10:6835-6842.
11. Astolfi A, Fiore M, Melchionda F, Indio V, Bertuccio SN, 
Pession A. BCOR involvement in cancer. Epigenomics. 
2019;11:835-855.
12. Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, 
Bruno S, et al. Aneuploid acute myeloid leukemia exhibits a 
signature of genomic alterations in the cell cycle and protein 
degradation machinery. Cancer. 2019;125:712-725.
13. Fujiwara Y, Chang AN, Williams AM, Orkin SH. Functional 
overlap of GATA-1 and GATA-2 in primitive hematopoietic 
development. Blood. 2004;103:583-585.
14. Ishida H, Imai K, Honma K, Tamura S, Imamura T, Ito M, 
et al. GATA-2 anomaly and clinical phenotype of a sporadic 
case of lymphedema, dendritic cell, monocyte, B- and NK-
cell (DCML) deficiency, and myelodysplasia. Eur J Pediatr. 
2012;171:1273-1276.
15. Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency 
and rela ted myeloid neoplasms.  Semin Hematol . 
2017;54:81-86.
16. Dotta L, Badolato R. Primary immunodeficiencies appearing 
as combined lymphopenia, neutropenia, and monocytopenia. 
Immunol Lett. 2014;161:222-225.
17. Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. 
Curr Opin Allergy Clin Immunol. 2015;15:104-109.
18. Mendes-de-Almeida DP, Andrade FG, Borges G, Dos 
Santos-Bueno FV, Vieira IF, da Rocha L, et al. GATA2 
mutation in long stand Mycobacterium kansasii infection, 
myelodysplasia and MonoMAC syndrome: A case-report. 
BMC Med Genet. 2019;20:64.
19. Parta M, Cuellar-Rodriguez J, Freeman AF, Gea-Banacloche 
J, Holland SM, Hickstein DD. Resolution of multifocal 
Epstein-Barr Virus -related smooth muscle tumor in a 
patient with GATA2 deficiency following hematopoietic 
stem cell transplantation. J Clin Immunol. 2017;37:61-66.
20. Bigley V, Collin M. Dendritic cell, monocyte, B and 
NK lymphoid deficiency defines the lost lineages of a 
new GATA-2 dependent myelodysplastic syndrome. 
Haematologica. 2011;96:1081-1083.
21. Griese M, Zarbock R, Costabel U, Hildebrandt J, Theegarten 
D, Albert M, et al. GATA2 deficiency in children and adults 
with severe pulmonary alveolar proteinosis and hematologic 
disorders. BMC Pulm Med. 2015;15:87.
22. Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, 
Masetti R, et al. Prevalence, clinical characteristics, and 
prognosis of GATA2-related myelodysplastic syndromes in 
children and adolescents. Blood. 2016;127:1387-1397; quiz 
518.
23. Dhall G, O’Neil SH, Ji L, Haley K, Whitaker AM, Nelson 
MD, et al. Excellent outcome of young children with 
nodular desmoplastic medulloblastoma treated on “Head 
Start” III: A multi-institutional, prospective clinical trial. 
Neuro Oncol. 2020;noaa102.
24. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, 
Reifenberger G, Burger PC, et al. The WHO classification 
of tumors of the nervous system. J Neuropathol Exp Neurol. 
2002;61:215-225; discussion 226-229.
25. Northcott PA, Buchhalter I, Morrissy AS, Hovestadt 
V, Weischenfeldt J, Ehrenberger T, et al. The whole-
genome landscape of medulloblastoma subtypes. Nature. 
2017;547:311-317.
26. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The 
clinical implications of medulloblastoma subgroups. Nat 
Rev Neurol. 2012;8:340-351.
27. Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, 
Pomeroy SL, Clifford SC, et al. Medulloblastoma. Nat Rev 
Dis Primers. 2019;5:11.
28. Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, 
Mynarek M, et al. Second-generation molecular subgrouping 
of medulloblastoma: An international meta-analysis 
of Group 3 and Group 4 subtypes. Acta Neuropathol. 
210 wileyonlinelibrary.com/journal/ped4
2019;138:309-326.
29. Glade Bender J, Verma A, Schiffman JD. Translating 
genomic discoveries to the clinic in pediatric oncology. Curr 
Opin Pediatr. 2015;27:34-43.
30. Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi 
V, et al. Clinical genomic profiling to identify actionable 
alterations for investigational therapies in patients with 
diverse sarcomas. Oncotarget. 2017;8:39254-39267.
31. Gallego S, Llort A, Roma J, Sabado C, Gros L, de 
Toledo JS. Detection of bone marrow micrometastasis 
and microcirculating disease in rhabdomyosarcoma by 
a real-time RT-PCR assay. J Cancer Res Clin Oncol. 
2006;132:356-362.
32. Abbasi MR, Rifatbegovic F, Brunner C, Mann G, Ziegler A, 
Potschger U, et al. Impact of disseminated neuroblastoma 
cells on the identification of the relapse-seeding clone. Clin 
Cancer Res. 2017;23:4224-4232.
33. Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh 
WW, Rytting ME, et al. Clinical next generation sequencing 
of pediatric-type malignancies in adult patients identifies 
novel somatic aberrations. Oncoscience. 2015;2:187-192.
34. Ali NM, Niada S, Brini AT, Morris MR, Kurusamy 
S,  Alhol le  A,  e t  a l .  Genomic and t ranscr iptomic 
characterisation of undifferentiated pleomorphic sarcoma of 
bone. J Pathol. 2019;247:166-176.
35. Pei J, Zhao X, Patchefsky AS, Flieder DB, Talarchek JN, 
Testa JR, et al. Clinical application of RNA sequencing in 
sarcoma diagnosis: An institutional experience. Medicine 
(Baltimore). 2019;98:e16031.
36. Miele E, De Vito R, Ciolfi A, Pedace L, Russo I, De 
Pasquale MD, et al. DNA methylation profiling for 
diagnosing undifferentiated sarcoma with Capicua 
transcriptional receptor (CIC) alterations. Int J Mol Sci. 
2020;21:1818.
37. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones 
DTW, Capper D, et al. New brain tumor entities emerge 
from molecular classification of CNS-PNETs. Cell. 
2016;164:1060-1072.
How to cite this article: Chan GC, Chan CM. Genotypes 
versus phenotypes: The potential paradigm shift in the diagnosis 
and management of pediatric neoplasms. Pediatr Investig. 
2020;4:204-210. https://doi.org/10.1002/ped4.12211  
